NAV

Polycarbophil

Identification

Generic Name
Polycarbophil
DrugBank Accession Number
DB09311
Background

Polycarbophil calcium is a synthetic polymer manufactured from the cross-linking of polyacrylic acid with divinyl glycol and a calcium counter-ion. Polycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.

Type
Small Molecule
Groups
Experimental
Synonyms
  • Policarbofila
  • Polycarbofil
  • Polycarbophil
  • Polycarbophile
  • Polycarbophilum
External IDs
  • WL 140
  • WL-140

Ph值armacology

Indication

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
构建、培训和验证预测machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Ph值armacodynamics

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Mechanism of action

It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.

Absorption

Calcium polycarbophil is not absorbed from the intestine.

Volume of distribution

Calcium polycarbophil is not absorbed from the intestine.

Protein binding

Calcium polycarbophil is not absorbed from the intestine.

Metabolism

Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.

Route of elimination

Excreted in feces.

Half-life

Calcium polycarbophil is not absorbed from the intestine.

Clearance

Calcium polycarbophil is not absorbed from the intestine.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.

Pathways
Not Available
Ph值armacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Polycarbophil.
Aclidinium The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Aclidinium.
Alfentanil The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Alfentanil.
Alloin The risk or severity of adverse effects can be increased when Polycarbophil is combined with Alloin.
Amantadine The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amantadine.
Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Polycarbophil.
Amiodarone The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amiodarone.
Amitriptyline The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amitriptyline.
Amlodipine The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amlodipine.
Amobarbital The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amobarbital.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Fibercon/Mitrolan

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
W25LM17A4W
CAS number
9003-97-8

References

一般引用
  1. Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [Article]
  2. Monograph [Link]
  3. webmd [Link]
KEGG Drug
D03306
PubChem Substance
347910435
Wikipedia
Polycarbophil_calcium

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Ph值ase Status Purpose Conditions Count
2 Recruiting Supportive Care Female Breast Cancer/Long-Term Survivors/Postmenopausal Syndrome/Vulvo Vaginal Atrophy 1
Not Available Completed Treatment Type 2 Diabetes Mellitus 1

Ph值armacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Granule
Tablet
Tablet, chewable Oral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 16, 2015 21:57 / Updated at April 15, 2023 12:42